Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Stiff

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaTimothy S Fenske, Parameswaran N Hari, Jeanette Carreras, et al.
Transplantation and Cellular Therapy|November 25, 2022
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation SurvivorsSanghee Hong, Jing Zhao, Shu Wang, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Transplantation and Cellular Therapy|February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsChenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaTimothy S Fenske, Parameswaran N Hari, Jeanette Carreras, et al.
Transplantation and Cellular Therapy|November 25, 2022
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation SurvivorsSanghee Hong, Jing Zhao, Shu Wang, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Transplantation and Cellular Therapy|February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsChenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Pageof 6